GI-5005: Additional Phase IIb data

GlobeImmune reported data from the 38 prior non-responders enrolled in an open-label Phase IIb trial showing that GI-5005 plus standard of care (SOC; Pegasys peginterferon alfa-2a and Copegus ribavirin) led to an SVR rate of 17% vs. 5% for SOC alone. Prior non-responders were defined as patients who did not clear their virus after a minimum of 12 weeks of SOC, and included null, poor and partial responders. The trial enrolled 140 patients who were treatment-naïve (n=102) or prior non-responders. Data were presented at the American Association for the Study of Liver Diseases meeting in Boston. ...